Efficacy and safety of combining olodaterol Respimat® and tiotropium HandiHaler® in patients with COPD: Results of two randomized, double-blind, active-controlled studies

International Journal of COPD

Volumn 9, Issue , 2014, Pages 1133-1144

  ZuWallack, Richard ^a   Allen, Lisa ^b   Hernandez, Gemzel ^b   Ting, Naitee ^b   Abrahams, Roger ^c  

^a SAINT FRANCIS HOSPITAL AND MEDICAL CENTER   (United States)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^c Morgantown Pulmonary Clinical Research   (United States)

Author keywords

Bronchodilator; Long acting beta2 agonist; Long acting muscarinic antagonist; Olodaterol Respimat ; Tiotropium HandiHaler

Indexed keywords

OLODATEROL PLUS TIOTROPIUM BROMIDE; PLACEBO; TIOTROPIUM BROMIDE; BENZOXAZINE DERIVATIVE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; OLODATEROL; SCOPOLAMINE DERIVATIVE;

ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; BACKACHE; BRONCHITIS; BRONCHODILATING ACTIVITY; CANDIDIASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY POWDER INHALER; DYSPHONIA; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; HYPERTENSION; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MUSCLE SPASM; NAUSEA; OUTCOME ASSESSMENT; PARALLEL DESIGN; PATIENT COMPLIANCE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REPLICATION STUDY; RHINOPHARYNGITIS; SINUSITIS; SOFT MIST INHALER; SPIROMETRY; ST. GEORGE RESPIRATORY QUESTIONNAIRE; THORAX PAIN; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; XEROSTOMIA; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECTS; EQUIPMENT DESIGN; INHALATIONAL DRUG ADMINISTRATION; LUNG; MIDDLE AGED; NEBULIZER; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRE; TIME; TREATMENT OUTCOME; UNITED STATES;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; BENZOXAZINES; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EQUIPMENT DESIGN; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LUNG; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; NEBULIZERS AND VAPORIZERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRES; SCOPOLAMINE DERIVATIVES; SPIROMETRY; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84907808594     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S72482     Document Type: Article

References (26)

1. Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011;155(3):179-191.
2. National Heart, Lung, and Blood Institute [homepage on the Internet]. NHLBI Factbook. 4. Disease Statistics [updated 2006]. Available from: http://www.nhlbi.nih.gov/about/factbook-06/chapter4data.htm. Accessed March 21, 2014.
3. Global Initiative for Chronic Obstructive Lung Disease [homepage on the Internet]. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2013 [updated 2013]. Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2013_Feb20.pdf. Accessed March 5, 2014.
4. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002;19(2):217-224.
5. O’Donnell DE, Flüge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J. 2004;23(6):832-840.
6. Maltais F, Hamilton A, Marciniuk D, et al. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest. 2005;128(3):1168-1178.
7. Keating GM. Tiotropium bromide inhalation powder: a review of its use in the management of chronic obstructive pulmonary disease. Drugs. 2012;72(2):273-300.
8. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15): 1543-1554.
9. Feldman G, Bernstein JA, Hamilton A, Nivens C, LaForce C. The 24-hour FEV1 time profile of olodaterol once daily (QD) via Respimat® and formoterol twice daily (BID) via Aerolizer® in patients with COPD: results from two 6-week studies. Chest. 2013;144 (No 4 Meeting Abstracts):749A (abstract).
10. Lange P, Aumann J-L, Derom E, et al. The 24-h FEV1 time profile of olodaterol QD delivered via Respimat® in COPD: Results from two 6-week studies. Eur Respir J. 2013;42(Suppl 57):982s, 4635 (abstract).
11. Koch A, Pizzichini E, Hamilton A, et al. Lung function efficacy of olodaterol QD delivered via Respimat® vs placebo and formoterol BID in patients with COPD: Two 48-week studies. Eur Respir J. 2013;42 (Suppl 57):146s, P764 (abstract).
12. Ferguson G, Feldman G, Hofbauer P, et al. Lung function efficacy of olodaterol QD delivered via Respimat® in COPD patients: Results from two 48-week studies. Eur Respir J. 2013;42(Suppl 57):5s, 187 (abstract).
13. Tashkin DP, Ferguson GT. Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respir Res. 2013;14:49.
14. Boehringer Ingelheim. Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®. Available from http://clinicaltrials.gov/show/NCT01694771.Identifier: NCT1694771. Accessed September 23, 2014.
15. Boehringer Ingelheim. Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®. Available from http://clinicaltrials.gov/show/NCT01696058. Identifier: NCT1696058. Accessed September 23, 2014.
16. Jones PW, Beeh KM, Chapman KR, Decramer M, Mahler DA, Wedzicha JA. Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med. 2014;189(3):250-255.
17. COMBIVENT Inhalation Solution Study Group. Routine nebulized ipratropium and albuterol together are better than either alone in COPD. Chest. 1997;112(6):1514-1521.
18. van Noord JA, Aumann J-L, Janssens E, et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J. 2005;26(2):214-222.
19. Decramer M, Wedzicha JA, Sandström T, et al. Safety and tolerability of QVA149, glycopyrronium and tiotropium in patients with severe to very severe COPD: the SPARK study. Abstract presented at the American Thoracic Society Annual Meeting, Philadelphia PA, USA, May 17-21, 2013.
20. Decramer M, Anzueto A, Kerwin E, et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med. 2014;2(6):472-486.
21. Mahler DA, D’Urzo A, Bateman ED, et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison. Thorax. 2012;67:781-788.
22. Kessler R, Partridge MR, Miravitlles M, et al. Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J. 2011;37(2):264-272.
23. Dahl R, Jadayel D, Alagappan VKT, Chen H, Banerji D. Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study. Int J Chron Obstruct Pulmon Dis. 2013;8:501-508.
24. Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013;42(6):1484-1494.
25. Donohue JF, Niewoehner D, Brooks J, O’Dell D, Church A. Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study. Respir Res. 2014;15(1):78.
26. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009;33(5):1165-1185.